Literature DB >> 14872000

The effects of macrolides on inflammatory cells.

Jun Tamaoki1.   

Abstract

Bronchial epithelial damage and mucus hypersecretion are characteristic features of chronic airway inflammation that can impair mucociliary clearance and can cause recurrent or persistent respiratory infection. In response to chemoattractants produced by damaged or inflamed tissue, neutrophils move through sequential steps of recruitment, migration, accumulation, and adhesion to endothelial and bronchial epithelial cells. Neutrophils engage in bacteriocidal activity by phagocytosis, release of lysosomal enzymes, and generation of reactive oxygen species, and they synthesize and release proinflammatory cytokines. Data confirm that many macrolide antibiotics have nonbactericidal properties that include inhibiting inflammatory cell chemotaxis, cytokine synthesis, adhesion molecule expression, and reactive oxygen species production. Macrolides also can decrease airway mucus hypersecretion in patients with diffuse panbronchiolitis, chronic sinusitis, and chronic bronchitis. Macrolides accumulate in neutrophils and macrophages at significantly higher concentrations than in extracellular fluid. This article discusses the action of macrolides on neutrophil accumulation, immune complex-mediated production of nitric oxide, mucin production, and the expanded therapeutic role of macrolides as biological response modifiers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14872000     DOI: 10.1378/chest.125.2_suppl.41s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  33 in total

1.  Macrolide immunomodulation of chronic respiratory diseases.

Authors:  Daniel P Healy
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

2.  [A 63 year old Turkish woman with recurrent pneumonia].

Authors:  M Breidert; R Janssen-Langenstein; S Hambrecht
Journal:  Internist (Berl)       Date:  2007-04       Impact factor: 0.743

Review 3.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 4.  The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP).

Authors:  Gretchen M Oakley; Richard J Harvey; Valerie J Lund
Journal:  Curr Allergy Asthma Rep       Date:  2017-05       Impact factor: 4.806

Review 5.  Cellular and molecular biology of airway mucins.

Authors:  Erik P Lillehoj; Kosuke Kato; Wenju Lu; Kwang C Kim
Journal:  Int Rev Cell Mol Biol       Date:  2013       Impact factor: 6.813

Review 6.  Efficacy and safety of long-term antibiotics (macrolides) for the treatment of chronic rhinosinusitis.

Authors:  Anders Cervin; Ben Wallwork
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

7.  Resolution of chronic ocular sarcoidosis with antimycobacterial therapy.

Authors:  Bradley W Richmond; Kyra Richter; Lloyd E King; Wonder P Drake
Journal:  Case Rep Intern Med       Date:  2014

Review 8.  Inflammatory properties of antibiotic-treated bacteria.

Authors:  Andrea J Wolf; George Y Liu; David M Underhill
Journal:  J Leukoc Biol       Date:  2016-08-30       Impact factor: 4.962

9.  Ceftiofur regulates LPS-induced production of cytokines and improves LPS-induced survival rate in mice.

Authors:  Xinxin Ci; Hongyu Li; Yu Song; Na An; Qinlei Yu; Fanqin Zeng; Xuming Deng
Journal:  Inflammation       Date:  2008-12       Impact factor: 4.092

10.  Airways disease: phenotyping heterogeneity using measures of airway inflammation.

Authors:  Salman Siddiqui; Christopher E Brightling
Journal:  Allergy Asthma Clin Immunol       Date:  2007-06-15       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.